PURPOSE The (MC)2 score is a renal ablation-specific risk scoring system to predict major complications from percutaneous renal cryoablation (PRCA). However, it is untested in an external population of patients. The purpose of this study is to validate the ability of the (MC)2 score to predict major complications after PRCA in an external population. MATERIALS AND METHODS Retrospective review of patients who underwent PRCA from 2004 to 2019. Patient demographics, medical histories, and tumor characteristics were collected. The (MC)2 score was calculated and patients were assigned to low risk (< 5), moderate risk (5-8) and high-risk (> 8) groups. Complications were recorded. Major complications were classified according to CIRSE guidelines. RESULTS Two hundred and one patients [M = 116; F = 85; median age = 65 (range 27-90)] met inclusion criteria. Eleven patients (5.5%) developed major complications and 50 patients (24.9%) developed minor complications. Of patients with major complications, mean tumor diameter was 39 mm (± 10.4), seven patients (63.6%) had a central tumor, four patients (36.4%) had complicated diabetes, and one patient (9.1%) had a prior MI. Major complication rates were 2.1%, 14%, and 14.3% in the (MC)2 low risk, moderate risk, and high risk groups, respectively. The mean (MC)2 score for patients with major complications [6.2 (± 2.4)] was higher than the mean score for patients with minor complications [4.7 (± 2.4) (p = 0.07)] and no complications [3.9 (± 1.9) (p < 0.01)]. The area under the ROC curve to predict major complications was 0.78. CONCLUSION The (MC)2 risk scoring system appropriately identifies patients at risk for major complications from PRCA in this external patient population.

中文翻译：

---

肾消融特异性 (MC)2 风险评分系统在预测经皮肾冷冻消融并发症方面的外部验证。

目的 (MC)2 评分是一种肾消融特异性风险评分系统，用于预测经皮肾冷冻消融 (PRCA) 的主要并发症。然而，它尚未在外部患者群体中进行测试。本研究的目的是验证 (MC)2 评分在外部人群中预测 PRCA 后主要并发症的能力。材料和方法 对 2004 年至 2019 年接受 PRCA 的患者进行回顾性研究。收集了患者的人口统计学、病史和肿瘤特征。计算 (MC)2 评分并将患者分配到低风险 (< 5)、中等风险 (5-8) 和高风险 (> 8) 组。记录并发症。根据 CIRSE 指南对主要并发症进行分类。结果 201 名患者 [M = 116; F = 85；中位年龄 = 65（范围 27-90）] 符合纳入标准。11 名患者 (5.5%) 出现严重并发症，50 名患者 (24.9%) 出现轻微并发症。在有严重并发症的患者中，平均肿瘤直径为 39 mm (± 10.4)，7 名患者 (63.6%) 为中心性肿瘤，4 名患者 (36.4%) 患有复杂的糖尿病，1 名患者 (9.1%) 有既往心梗。(MC)2 低风险、中风险和高风险组的主要并发症发生率分别为 2.1%、14% 和 14.3%。严重并发症患者的平均 (MC)2 评分 [6.2 (± 2.4)] 高于轻微并发症患者的平均评分 [4.7 (± 2.4) (p = 0.07)] 和无并发症 [3.9 (± 1.9) ) (p < 0.01)]。预测主要并发症的 ROC 曲线下面积为 0.78。